A detailed history of Midwest Professional Planners, Ltd. transactions in Bio N Tech Se stock. As of the latest transaction made, Midwest Professional Planners, Ltd. holds 3,829 shares of BNTX stock, worth $435,625. This represents 0.14% of its overall portfolio holdings.

Number of Shares
3,829
Previous 3,904 1.92%
Holding current value
$435,625
Previous $313,000 45.05%
% of portfolio
0.14%
Previous 0.11%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$78.36 - $124.66 $5,877 - $9,349
-75 Reduced 1.92%
3,829 $454,000
Q2 2024

Aug 06, 2024

BUY
$80.36 - $102.87 $58,421 - $74,786
727 Added 22.88%
3,904 $313,000
Q1 2024

May 09, 2024

BUY
$88.96 - $112.35 $18,859 - $23,818
212 Added 7.15%
3,177 $293,000
Q4 2023

Feb 15, 2024

BUY
$90.91 - $112.75 $13,000 - $16,123
143 Added 5.07%
2,965 $312,000
Q3 2023

Nov 13, 2023

BUY
$98.5 - $125.08 $21,670 - $27,517
220 Added 8.46%
2,822 $306,000
Q2 2023

Aug 07, 2023

BUY
$102.58 - $129.66 $33,133 - $41,880
323 Added 14.17%
2,602 $280,000
Q1 2023

May 15, 2023

BUY
$122.57 - $153.67 $18,753 - $23,511
153 Added 7.2%
2,279 $283,000
Q4 2022

Feb 10, 2023

BUY
$118.43 - $186.05 $28,541 - $44,838
241 Added 12.79%
2,126 $319,000
Q3 2022

Nov 10, 2022

BUY
$127.65 - $183.11 $13,530 - $19,409
106 Added 5.96%
1,885 $254,000
Q2 2022

Aug 09, 2022

BUY
$123.25 - $186.24 $20,952 - $31,660
170 Added 10.57%
1,779 $265,000
Q1 2022

May 11, 2022

BUY
$126.25 - $231.85 $23,735 - $43,587
188 Added 13.23%
1,609 $274,000
Q4 2021

Feb 10, 2022

BUY
$216.64 - $362.52 $4,766 - $7,975
22 Added 1.57%
1,421 $366,000
Q3 2021

Nov 08, 2021

BUY
$205.93 - $447.23 $4,530 - $9,839
22 Added 1.6%
1,399 $380,000
Q2 2021

Aug 10, 2021

BUY
$113.32 - $241.49 $156,041 - $332,531
1,377 New
1,377 $308,000

Others Institutions Holding BNTX

About BioNTech SE


  • Ticker BNTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 242,684,992
  • Market Cap $27.6B
  • Description
  • BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...
More about BNTX
Track This Portfolio

Track Midwest Professional Planners, Ltd. Portfolio

Follow Midwest Professional Planners, Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Midwest Professional Planners, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Midwest Professional Planners, Ltd. with notifications on news.